NVS-AAT
Phase 1
NovartisNVS-AAT is one of 17 therapeutic programs targeting Alpha-1 Antitrypsin Deficiency. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
31 competitors in Alpha-1 Antitrypsin Deficiency
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPhase 2
Benadryl
PParkedale
Phase 1
SAR447537
SanofiPhase 2
Zofran
NovartisPreclinical
RG6026
RochePhase 1
Alvelestat
UUniversity of Alabama at Birmingham
Phase 2
Biological NTLA-2002
Intellia TherapeuticsPhase 2
Duragesic
CCephalon
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for NVS-AAT. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1
- Company